Ardelyx Reports Q1 Revenue Growth and Provides Business Update
Ardelyx reported first-quarter product revenue of $93.4 million, driven by a 58% year-over-year increase in IBSRELA sales to $70.1 million. The company reiterated its full-year guidance for 2026 and outlined long-term goals including achieving at least $1 billion annual revenue from IBSRELA by 2029.
Tickers: $ARDX
Topics: financial guidance ibsrela pharmaceuticals pipeline development xphozah